Lv3
280 积分 2024-02-18 加入
Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC-0853, a Selective Reversible Bruton's Tyrosine Kinase Inhibitor
2天前
已完结
Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC-0853, a Selective Reversible Bruton's Tyrosine Kinase Inhibitor
2天前
已完结
Pharmacodynamic Markers (CD63, CD69, pBTK) Guide Dose Selection for Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis
2天前
已关闭
Accuracy of allometrically predicted pharmacokinetic parameters in humans: role of species selection
1个月前
已完结
Application of physiologically based pharmacokinetic modelling for the prediction of drug-drug interactions involving anlotinib as a perpetrator of cytochrome P450 enzymes
2个月前
已完结
Prediction of Drug-Drug Interactions with Ensartinib as a Time-Dependent CYP3A Inhibitor Using Physiologically Based Pharmacokinetic Model
2个月前
已完结
B cells move to centre stage: novel opportunities for autoimmune disease treatment
2个月前
已关闭
Pharmacokinetics, safety, and tolerability of the oral Renin inhibitor aliskiren in patients with hepatic impairment
3个月前
已完结
Pharmacokinetics of the Oral Direct Renin Inhibitor Aliskiren Alone and in Combination with Irbesartan in Renal Impairment
3个月前
已完结
Single-Dose Pharmacokinetics and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Subjects with Severe Renal Function Impairment
3个月前
已完结
皖公网安备34019202002308
